ArticleMedical oncology (Northwood, London, England)2005
Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia (B-CLL): comparison of indolent and progressive disease.
Article in Medical oncology (Northwood, London, England), 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 22 citations in OpenAlex.
- Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response.British journal of haematology · 2011Trial
- Recent revelations and future directions using single-cell technologies in chronic lymphocytic leukemia.Frontiers in oncology · 2023Review
- Chronic lymphocytic leukemia cells acquire regulatory B-cell properties in response to TLR9 and CD40 activation.Cancer immunology, immunotherapy : CII · 2018Article
- T cells from indolent CLL patients prevent apoptosis of leukemic B cells in vitro and have altered gene expression profile.Cancer immunology, immunotherapy : CII · 2013Article
- Molecular action of lenalidomide in lymphocytes and hematologic malignancies.Advances in hematology · 2012Article
- Article
- IFN gamma gene polymorphism may contribute to the susceptibility to CLL.Pathology oncology research : POR · 2010Article
- New treatments for chronic lymphocytic leukemia.Current oncology reports · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
T-cell dysfunction in B-CLL patients might be attributed to altered expression of components of the TCR/CD3 complex and associated intracellular tyrosine kinases. Four-color flow cytometry was applied to the expression of these molecules as well as the T-cell regulatory cytokines (IFN-gamma and IL-4) in B-CLL patients with indolent and progressive disease. Intracellular levels [mean fluorescent intensity (MFI)] of IFN-gamma and IL-4 in both CD4 and CD8 T cells of both patient groups were significantly higher than in healthy donors. Absolute number of IL-4 producing CD4 T cells in patients with indolent was significantly higher than in healthy donors. The expression level (MFI) of the CD3-zeta chain was higher in patients than in normal donors as well as ZAP-70 in patients with indolent disease as compared to healthy donors and progressive patients. No significant difference was noted in the expression of p56lck, p59fyn, and PI3-kinase between healthy donors and patients or between the patient subgroups. The results indicate multiple T-cell abnormalities especially in indolent-stage B-CLL suggesting a state of chronic and aberrant activation. This information might be of significance when studying the immunobiology of B-CLL as well as developing new therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.